Prof. Wolf-Henning Boehncke (University of Geneva, Switzerland) provided an unorthodox presentation about psoriatic arthritis (PsA), highlighting aspects that are, as he put it, “to the left and right of what is in the current limelight” . He argued that the lack of PsA-focussed outcome measures has possibly hindered the progress of innovative biologics in PsA patients as the gold standard of care, and he predicts that treat-to-target using minimal disease activity as an objective will be the future of timely and effective PsA management.
Steadily increasing recognition is being awarded to the fact that -like psoriasis of the skin- PsA can be multifaceted; however, unlike rheumatoid arthritis, PsA can affect tissues beyond the joints . For example, Prof. Boehncke detailed, inflammation in PsA can result in swelling of an entire toe, especially associated tendons and their entheses (attachments to bone). There is an enormous benefit in coupling the kn...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Favourable safety profile of long-term use of ixekizumab Next Article
How Can Societies Help to Implement Personalised Treatment? »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.